Gemzar gemcitabine: Phase III data

Researchers at the University of Liverpool and colleagues reported data from the open-label, international Phase III ESPAC-3 trial in 1,088

Read the full 204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE